BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30101273)

  • 1. Targeting STING with cyclic di-GMP greatly augmented immune responses of glycopeptide cancer vaccines.
    Wu JJ; Li WH; Chen PG; Zhang BD; Hu HG; Li QQ; Zhao L; Chen YX; Zhao YF; Li YM
    Chem Commun (Camb); 2018 Aug; 54(69):9655-9658. PubMed ID: 30101273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
    Li M; Yu F; Yao C; Wang PG; Liu Y; Zhao W
    Org Biomol Chem; 2018 Feb; 16(6):993-999. PubMed ID: 29345713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and Immunological Evaluation of Disaccharide Bearing MUC-1 Glycopeptide Conjugates with Virus-like Particles.
    Wu X; McKay C; Pett C; Yu J; Schorlemer M; Ramadan S; Lang S; Behren S; Westerlind U; Finn MG; Huang X
    ACS Chem Biol; 2019 Oct; 14(10):2176-2184. PubMed ID: 31498587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
    Glaffig M; Stergiou N; Schmitt E; Kunz H
    ChemMedChem; 2017 May; 12(10):722-727. PubMed ID: 28440596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization.
    McDonald DM; Hanna CC; Ashhurst AS; Corcilius L; Byrne SN; Payne RJ
    ACS Chem Biol; 2018 Dec; 13(12):3279-3285. PubMed ID: 30359529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STING Activator c-di-GMP-Loaded Mesoporous Silica Nanoparticles Enhance Immunotherapy Against Breast Cancer.
    Chen YP; Xu L; Tang TW; Chen CH; Zheng QH; Liu TP; Mou CY; Wu CH; Wu SH
    ACS Appl Mater Interfaces; 2020 Dec; 12(51):56741-56752. PubMed ID: 33305564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MUC1-derived glycopeptide libraries with improved MHC anchors are strong antigens and prime mouse T cells for proliferative responses to lysates of human breast cancer tissue.
    Gad M; Jensen T; Gagne R; Komba S; Daugaard S; Kroman N; Meldal M; Werdelin O
    Eur J Immunol; 2003 Jun; 33(6):1624-32. PubMed ID: 12778480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MPYS/STING-mediated TNF-α, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo.
    Blaauboer SM; Gabrielle VD; Jin L
    J Immunol; 2014 Jan; 192(1):492-502. PubMed ID: 24307739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and immunological evaluation of self-assembling and self-adjuvanting tricomponent glycopeptide cancer-vaccine candidates.
    Wilkinson BL; Day S; Chapman R; Perrier S; Apostolopoulos V; Payne RJ
    Chemistry; 2012 Dec; 18(51):16540-8. PubMed ID: 23090901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Glucan as an immune activator and a carrier in the construction of a synthetic MUC1 vaccine.
    Wang H; Yang B; Wang Y; Liu F; Fernández-Tejada A; Dong S
    Chem Commun (Camb); 2018 Dec; 55(2):253-256. PubMed ID: 30534737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells.
    Cai H; Sun ZY; Chen MS; Zhao YF; Kunz H; Li YM
    Angew Chem Int Ed Engl; 2014 Feb; 53(6):1699-703. PubMed ID: 24449389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection.
    Soares MM; Mehta V; Finn OJ
    J Immunol; 2001 Jun; 166(11):6555-63. PubMed ID: 11359807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
    Jin JW; Tang SQ; Rong MZ; Zhang MQ
    Acta Biomater; 2018 Sep; 78():211-223. PubMed ID: 30098441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues.
    Gaidzik N; Kaiser A; Kowalczyk D; Westerlind U; Gerlitzki B; Sinn HP; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2011 Oct; 50(42):9977-81. PubMed ID: 21910197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycopeptide-functionalized gold nanoparticles for antibody induction against the tumor associated mucin-1 glycoprotein.
    Cai H; Degliangeli F; Palitzsch B; Gerlitzki B; Kunz H; Schmitt E; Fiammengo R; Westerlind U
    Bioorg Med Chem; 2016 Mar; 24(5):1132-5. PubMed ID: 26853835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust immune responses elicited by a fully synthetic three-component vaccine.
    Ingale S; Wolfert MA; Gaekwad J; Buskas T; Boons GJ
    Nat Chem Biol; 2007 Oct; 3(10):663-7. PubMed ID: 17767155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response.
    Kaiser A; Gaidzik N; Westerlind U; Kowalczyk D; Hobel A; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2009; 48(41):7551-5. PubMed ID: 19685547
    [No Abstract]   [Full Text] [Related]  

  • 19. Microarray Analysis of Antibodies Induced with Synthetic Antitumor Vaccines: Specificity against Diverse Mucin Core Structures.
    Pett C; Cai H; Liu J; Palitzsch B; Schorlemer M; Hartmann S; Stergiou N; Lu M; Kunz H; Schmitt E; Westerlind U
    Chemistry; 2017 Mar; 23(16):3875-3884. PubMed ID: 27957769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced immunogenicity of multivalent MUC1 glycopeptide antitumour vaccines based on hyperbranched polymers.
    Glaffig M; Palitzsch B; Stergiou N; Schüll C; Strassburger D; Schmitt E; Frey H; Kunz H
    Org Biomol Chem; 2015 Oct; 13(40):10150-4. PubMed ID: 26299280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.